This was a 1-month, multicenter, open-label, randomized study to determine single- and multiple-dose pharmacokinetics of d,l-methylphenidate (MPH) after MPH transdermal system (MTS) and osmotic-release oral system MPH (OROS MPH) dosing in children (6-12 years) and adolescents (…)
[Read article]
[Source: NCBI PubMed]
CAMBRIDGE, Mass.-(BUSINESS WIRE)-Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, and Shire plc (LSE: SHP, NASDAQ: SHPGY), the (…)
[Read article]
[Source: BioSpace]
MENLO PARK, Calif. September 8, 2010 Sofinnova Ventures, a venture capital firm based in Silicon Valley, today announced that Garheng Kong, M.D., Ph.D. has joined the firm as General Partner. He will actively invest in biopharmaceutical companies from the firm s current fund, (…)
[Read article]
[Source: BioSpace]
AP - NEW YORK Federal regulators have backed off a plan to remove a Shire PLC low blood-pressure treatment from the market after warning in August that the drug has not been proven effective.
[Read article]
[Source: BioSpace]
Oxford, UK and Langhorne, PA, USA 1 September 2010 EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Stephen A. Stamp to the company s Board as an independent Non-Executive (…)
[Read article]
[Source: BioSpace]
30.08.2010 - Shire plc announced that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease. VPRIV has been authorized as an (…)
[Read article]
[Source: Bionity.com]
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term (…)
[Read article]
[Source: Medical News Today]
Cambridge, MA, US August, 27th 2010 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV (velaglucerase alfa), a human cell line derived enzyme replacement (…)
[Read article]
[Source: BioSpace]
DUBLIN and PHILADELPHIA, August 24, 2010 /PRNewswire-FirstCall/ - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that its subsidiary Shire Pharmaceuticals Inc. received a ruling from the FDA on its Citizen's Petition relating to (…)
[Read article]
[Source: BioSpace]
EDISON, N.J.-(BUSINESS WIRE)-Oceana Therapeutics, a forward-thinking global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, today announced that John T. Spitznagel, Chairman & CEO, has been featured in PharmaVOICE s 2010 (…)
[Read article]
[Source: Business Wire]
FORT LAUDERDALE, Fla.-(BUSINESS WIRE)-BioFlorida today announced an impressive roster of keynote speakers for its 13th Annual Conference that includes the former Secretary of the U.S. Department of Health and Human Services, biotechnology entrepreneurs, executives and medical (…)
[Read article]
[Source: Business Wire]
PHILADELPHIA, Pennsylvania, August 17, 2010 /PRNewswire-FirstCall/ - Shire plc (LSE: SHP, NASDAQ: SHPGY) acquired ProAmatine as a part of the acquisition of Roberts Pharma in 1999 and Shire conducted and completed the post marketing trials that the FDA required. The FDA, (…)
[Read article]
[Source: BioSpace]
AP - Shire PLC said Tuesday it will pull a blood-pressure drug off the market following warnings from federal regulators who said the drug has not been proven effective.
[Read article]
[Source: BioSpace]
MIAMI-(BUSINESS WIRE)-Noven Pharmaceuticals, Inc. today announced that it has entered into a Product and Trademark Acquisition Agreement (the Agreement ) with affiliates of Shire plc ( Shire ) pursuant to which Noven will acquire global rights to Daytrana (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/4ac227/controlledrelease) has announced the addition of the "Controlled-release: Players, products & prospects to 2018 (Volume I)" report to their offering. Controlled-release: Players, (…)
[Read article]
[Source: Business Wire]
PHILADELPHIA-(BUSINESS WIRE)-High schools throughout Southeastern Pennsylvania are invited to join Shire s The Great Food Fight!, the first regional student food drive to fight hunger. The goal: to collect 25 tons of food the equivalent of 50,000 meals for Philabundance and (…)
[Read article]
[Source: Business Wire]
These studies investigated the absorption and metabolic conversion of lisdexamfetamine dimesylate (LDX), a prodrug stimulant that requires conversion to d-amphetamine for activity. Oral absorption of LDX was assessed in rat portal and jugular blood, and perfusion of LDX into (…)
[Read article]
[Source: NCBI PubMed]
Highlighted Links Conference Overview To Register NEW YORK, NY-(Marketwire - July 20, 2010) - iiBIG presents the Next Generation Pharma Sales & Marketing Summit, to be held November 16-17, 2010 at the Inner Harbor Marriott Hotel in Baltimore, MD. This networking and (…)
[Read article]
[Source: Marketwire]
Lainate, Italy 12 July 2010 Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today reports that Shire plc (LSE: SHP, NASDAQ: SHPGY) announced on July 8, 2010 that it has filed a law suit in the U.S. District Court of Delaware against Cadila Healthcare limited, doing business as Zydus (…)
[Read article]
[Source: BioSpace]
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in (…)
[Read article]
[Source: Medical News Today]
ROCKVILLE, MD-(Marketwire - July 12, 2010) - MarketResearch.com has announced the addition of GlobalData's new report "HIV-AIDS - Pipeline Assessment and Market Forecasts to 2016," to their collection of Diseases & Conditions market reports. For more information, visit (…)
[Read article]
[Source: Marketwire]
Dublin, Ireland and Philadelphia, US July 6, 2010 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana (methylphenidate transdermal system) for the treatment of Attention (…)
[Read article]
[Source: BioSpace]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/db9383/adhd_therapeutics) has announced the addition of the "ADHD Therapeutics - Global Strategic Business Report" report to their offering. ADHD Therapeutics - Global Strategic Business (…)
[Read article]
[Source: Business Wire]
28 June 2010 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, was named Company of the Year at the European Mediscience Awards 2010. All quoted European mediscience companies are eligible for the European Mediscience Awards, provided that the (…)
[Read article]
[Source: BioSpace]
Epoetin-delta (Dynepo Shire Pharmaceuticals, Basing stoke, UK) is a synthetic form of erythropoietin (EPO) whose resemblance with endogenous EPO makes it hard to identify using the classical identification criteria. Urine samples collected from six healthy volunteers treated (…)
[Read article]
[Source: NCBI PubMed]
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that Dr David Ginsburg and Ms Anne Minto OBE, have been appointed to the Shire Board of Directors with immediate effect. Dr Ginsburg, MD is currently Professor of Internal Medicine & (…)
[Read article]
[Source: BioSpace]
Lainate, Italy 31 May 2010 Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today reports that Shire plc (LSE: SHP, NASDAQ: SHPGY) announced on 28 May 2010 that it has received a Paragraph IV Notice Letter from Zydus Pharmaceuticals USA, Inc. ( Zydus ) advising of the filing of an (…)
[Read article]
[Source: BioSpace]
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of (…)
[Read article]
[Source: Medical News Today]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/194007/inflammatory_bowel) has announced the addition of the "Inflammatory Bowel Disease Therapeutics - Global Strategic Business Report" report to their offering. Inflammatory Bowel (…)
[Read article]
[Source: Business Wire]
Boston Globe - Drug maker Shire Pharmaceuticals is buying four buildings in Raytheon s former Lexington campus along Route 2 for more than $200 million, marking a major move forward for the recovering commercial real estate market.
[Read article]
[Source: BioSpace]
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced the results of a study evaluating the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) (…)
[Read article]
[Source: Medical News Today]
EDISON, N.J.-(BUSINESS WIRE)-Oceana Therapeutics today announced that the Company s President and COO, David S. Tierney, MD, has been featured in the first ever listing of the Irish Life Science 50. I have known David for years and am pleased to call him a friend as well as (…)
[Read article]
[Source: Business Wire]
NAPA, Calif.-(BUSINESS WIRE)-The 12th Annual C21 BioVentures Conference takes place May 25-27, 2010 at The Meritage Resort in Napa, CA. Links to important information: Overview Participants Program Business Wire is the official newswire service for the 12th Annual C21 (…)
[Read article]
[Source: Business Wire]
DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d5a60b/neurodegenerative) has announced the addition of the "Neurodegenerative Drugs - Global Strategic Business Report" report to their offering. Neurodegenerative Drugs - Global (…)
[Read article]
[Source: Business Wire]
Reuters - U.S. regulators have warned Roche Holding AG unit Genentech and Shire Plc about misleading promotions for cancer and bowel drugs, letters released on Wednesday said.
[Read article]
[Source: BioSpace]
DUBLIN, April 29, 2010 /PRNewswire-FirstCall/ - Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to March 31, 2010.
[Read article]
[Source: BioSpace]
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin (…)
[Read article]
[Source: Medical News Today]
DUBLIN, April 27, 2010 /PRNewswire-FirstCall/ - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter from Anchen Pharmaceuticals, Inc. ("Anchen") advising of the filing of an (…)
[Read article]
[Source: BioSpace]
KING OF PRUSSIA, Pa.-(BUSINESS WIRE)-The drive to share information across boundaries has helped make SharePoint the fastest growing product in Microsoft history. Steve Aylward, General Manager, U.S. Healthcare and Life Sciences Group for Microsoft, told this to more than 350 (…)
[Read article]
[Source: Business Wire]
DUBLIN and PHILADELPHIA, April 23, 2010 /PRNewswire-FirstCall/ - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that its subsidiary Shire LLC has filed a lawsuit in the U.S. District Court for the District of Delaware against (…)
[Read article]
[Source: BioSpace]
GUILDFORD, UK and BURLINGTON, MA-(Marketwire - April 14, 2010) - IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that Shire plc, the global specialty biopharmaceutical company, has selected IDBS to (…)
[Read article]
[Source: BioSpace]
ST. LOUIS, April 13 /PRNewswire-FirstCall/ - K-V Pharmaceutical Company (the "Company") today announced it has appointed Stephen A. Stamp as Chief Financial Officer and Treasurer, effective April 7, 2010. Mr. Stamp will report directly to David Van Vliet, interim CEO of the (…)
[Read article]
[Source: BioSpace]